Co-amlessa

Poland
Brand name Co-amlessa
Form tablets
Active substance / Dosage
perindopril tert-butylamine · 8 mg
amlodipine · 10 mg
indapamide · 2.5 mg
Prescription type Prescription only
ATC code
C09BX01
Registration number 100307592
Manufacturer Krka, d.d., Novo mesto Krka Polska Sp. z o.o. TAD Pharma GmbH
Co-amlessa tablets

Table of Contents

Package leaflet: Information for the patient

Co-Amlessa, 2 mg + 5 mg + 0.625 mg, tablets
Co-Amlessa, 4 mg + 5 mg + 1.25 mg, tablets
Co-Amlessa, 4 mg + 10 mg + 1.25 mg, tablets
Co-Amlessa, 8 mg + 5 mg + 2.5 mg, tablets
Co-Amlessa, 8 mg + 10 mg + 2.5 mg, tablets
tert-Butylamine perindopril + amlodipine + indapamide
Please read this leaflet carefully before using this medicine, as it contains important
information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any further questions, please ask your doctor or pharmacist.
  • This medicine has been prescribed for a specific individual. Do not pass it on to others. It may harm other people, even if their symptoms are the same.
  • If you experience any side effects, including any not listed in this leaflet, tell your doctor or pharmacist. See section 4.

Contents of the leaflet

  1. What Co-Amlessa is and what it is used for
  2. What you need to know before taking Co-Amlessa
  3. How to take Co-Amlessa
  4. Possible side effects
  5. How to store Co-Amlessa
  6. Contents of the pack and other information

1. What Co-Amlessa is and what it is used for

Co-Amlessa is used to treat high blood pressure (hypertension). All three active substances help control high blood pressure. Patients already taking perindopril/indapamide and amlodipine as separate tablets may switch to one tablet of Co-Amlessa containing all three components.
Co-Amlessa is a combination of three active substances: perindopril, indapamide, and amlodipine. Perindopril belongs to a group of medicines called angiotensin-converting enzyme (ACE) inhibitors. Amlodipine is a calcium antagonist (belongs to a group of medicines known as dihydropyridines). Indapamide is a diuretic.
In patients with high blood pressure, perindopril and amlodipine relax blood vessels, allowing blood to flow more easily. Indapamide increases the amount of urine produced by the kidneys. Each of the active substances lowers blood pressure, and together they effectively control blood pressure levels.

2. Important information before using Co-Amlessa

When not to use Co-Amlessa

  • if the patient is allergic to perindopril or any other ACE inhibitor, indapamide or any other sulfonamide, amlodipine besylate or any other dihydropyridine, or to any of the other ingredients of this medicine (listed in section 6);
  • if the patient has experienced symptoms such as wheezing, facial or tongue swelling, intense itching or severe skin rash during previous treatment with an ACE inhibitor, or if such symptoms occurred in the patient or a family member under any other circumstances (a condition known as angioedema);
  • if the patient has liver disease or a condition called hepatic encephalopathy (a liver disease causing brain damage);
  • if the patient has severe kidney function impairment (creatinine clearance below 30 ml/min);
  • if the patient has severe kidney disease causing reduced blood supply to the kidneys (renal artery stenosis). Co-Amlessa 8 mg + 5 mg + 2.5 mg and 8 mg + 10 mg + 2.5 mg are contraindicated in moderate or severe kidney disease;
  • if the patient is undergoing dialysis or blood filtration by another method. Depending on the device used, Co-Amlessa may not be suitable for the patient;
  • if the patient has low or high potassium levels in the blood;
  • if there is suspicion of untreated, uncompensated heart failure (symptoms include fluid retention in the body and breathing difficulties);
  • if the patient has cardiogenic shock (a condition in which the heart cannot deliver sufficient blood to meet the body's needs), aortic stenosis (narrowing of the main blood vessel leaving the heart), or unstable angina (chest pain that may occur at rest);
  • if the patient has very low blood pressure (severe hypotension);
  • if the patient has heart failure (the heart is unable to pump blood effectively, leading to breathlessness and peripheral oedema, e.g. in legs, ankles or feet) following acute myocardial infarction;
  • if the patient is pregnant beyond 3 months (use of Co-Amlessa is also not recommended during early pregnancy – see "Pregnancy and breastfeeding");
  • if the patient has diabetes or kidney dysfunction and is being treated with a blood pressure-lowering medicine containing aliskiren;
  • if the patient is taking or currently using a combination medicine containing sacubitril and valsartan (used to treat certain types of chronic heart failure in adults), as this increases the risk of angioedema (rapid swelling of tissues beneath the skin, such as in the throat).

Warnings and precautions
Before starting treatment with Co-Amlessa, discuss this with your doctor or pharmacist.

  • If the patient has recently had a myocardial infarction;
  • If the patient has aortic stenosis (narrowing of the main blood vessel leaving the heart), hypertrophic cardiomyopathy (a heart muscle disorder), or renal artery stenosis (narrowing of the artery supplying blood to the kidney);
  • If the patient has heart failure or any other heart disease;
  • If the patient has kidney disease or is undergoing dialysis;
  • If the patient has experienced a significant increase in blood pressure (hypertensive crisis);
  • If the patient has muscle disorders, including muscle pain, tenderness, weakness or cramps;
  • If the patient has abnormally high levels of a hormone called aldosterone in the blood (primary hyperaldosteronism);
  • If the patient has liver disorders;
  • If the patient has collagenosis (a skin disease), such as systemic lupus erythematosus or scleroderma;
  • If the patient has atherosclerosis (hardening of the arteries);
  • If the patient has hyperparathyroidism;
  • If the patient has gout;
  • If the patient has diabetes;
  • If the patient is on a salt-restricted diet or using potassium-containing salt substitutes;
  • If the patient is taking lithium or potassium-sparing diuretics (spironolactone, triamterene) or potassium supplements, as concomitant use with Co-Amlessa is not recommended (see "Co-Amlessa and other medicines");
  • If the patient is elderly and requires a dose increase;
  • If the patient has previously experienced photosensitivity reactions;
  • If the patient develops a severe allergic reaction with swelling of the face, lips, mouth, tongue or throat, which may cause difficulty in swallowing or breathing (angioedema). Swelling may occur at any time during treatment. If such symptoms occur, treatment must be discontinued and medical advice sought immediately;
  • If the patient is taking any of the following medicines for high blood pressure:
  • an angiotensin II receptor antagonist (ARB) (also known as sartans – e.g. valsartan, telmisartan, irbesartan), especially if the patient has kidney impairment related to diabetes,
  • aliskiren. The treating physician may monitor kidney function, blood pressure and blood electrolyte levels (e.g. potassium) at regular intervals. See also information under "When not to use Co-Amlessa".
  • If the patient is of Black race – in such cases, there may be an increased risk of angioedema, and the medicine may be less effective in lowering blood pressure compared to patients of other races;
  • If the patient is undergoing dialysis using high-flux membranes;
  • If the patient is taking any of the following medicines, which increase the risk of angioedema (rapid swelling of the skin in areas such as the throat):
  • racecadotril (used to treat diarrhoea),
  • sirolimus, everolimus, temsirolimus and other medicines belonging to the so-called mTOR inhibitors (used to prevent organ transplant rejection and in cancer treatment),
  • linagliptin, saxagliptin, sitagliptin, vildagliptin used in diabetes treatment,
  • sacubitril (available in a combination medicine containing sacubitril and valsartan), used in the treatment of chronic heart failure.

Angioedema
Cases of angioedema (a severe allergic reaction with swelling of the face, lips, tongue or throat and difficulty swallowing or breathing) have been reported in patients treated with ACE inhibitors, including Co-Amlessa. This reaction may occur at any time during treatment. If such symptoms occur, the patient must stop taking Co-Amlessa and seek immediate medical advice. See also section 4.
Inform your doctor if you are pregnant, suspect you may be pregnant, or are planning pregnancy. Use of Co-Amlessa is not recommended during early pregnancy and must not be used after the 3rd month of pregnancy, as it may seriously harm the unborn child if administered during this period (see section "Pregnancy and breastfeeding").
While taking Co-Amlessa, also inform your doctor or healthcare provider:

  • if you have a dry cough;

  • if you are to undergo general anaesthesia and/or surgery;

  • if you have recently had diarrhoea or vomiting, or if you are dehydrated;

  • if you are to undergo dialysis or LDL apheresis (removal of cholesterol from the blood using a special device);

  • if you are to undergo desensitisation to reduce allergic reactions following bee or wasp stings;

  • if you are to undergo imaging tests requiring iodine-containing contrast agents (substances that make organs such as kidneys or stomach visible on X-ray);

  • if you experience blurred vision or eye pain. These may be symptoms of fluid accumulation in the avascular membrane surrounding the eye (excessive fluid accumulation between choroid and sclera) or increased intraocular pressure – they may occur from several hours to weeks after taking Co-Amlessa. Untreated, they may lead to permanent vision loss. Patients with a history of penicillin or sulfonamide allergy may be at higher risk of developing this condition. Discontinue use of Co-Amlessa and consult your doctor.
    Athletes should be informed that Co-Amlessa contains an active substance (indapamide) that may lead to a positive result in doping tests.
    Children and adolescents
    Co-Amlessa is not recommended for use in children and adolescents.
    Co-Amlessa and other medicines
    Inform your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
    Avoid using Co-Amlessa with:

  • lithium (used to treat depression);

  • aliskiren (used to treat high blood pressure) in patients without diabetes or kidney dysfunction;

  • potassium-sparing diuretics (e.g. triamterene, amiloride), potassium salts, and other medicines that may increase potassium levels in the body (e.g. trimethoprim and co-trimoxazole, also known as trimethoprim/sulfamethoxazole, used for bacterial infections; cyclosporine, an immunosuppressive medicine used to prevent organ transplant rejection, and heparin, a medicine used to thin the blood to prevent clots);

  • sacubitril/valsartan (used to treat chronic heart failure). See sections "When not to use Co-Amlessa" and "Warnings and precautions"

  • estramustine (used to treat cancer);

  • other medicines used to treat high blood pressure: angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists.

Other medicines may affect the action of Co-Amlessa.
Inform your doctor if you are taking any of the following medicines, as special care may be required:

  • other medicines used to treat high blood pressure, including angiotensin II receptor antagonists (ARBs) or aliskiren (see also sections "When not to use Co-Amlessa" and "Warnings and precautions"), or diuretics (medicines that increase urine output by the kidneys);

  • potassium-sparing medicines used to treat heart failure: eplerenone and spironolactone at doses from 12.5 mg to 50 mg per day;

  • anaesthetics;

  • iodine-containing contrast agents;

  • moxifloxacin, sparfloxacin, rifampicin, erythromycin, clarithromycin (antibiotics used to treat infections);

  • methadone (used to treat addiction);

  • procainamide (used to treat heart rhythm disorders);

  • allopurinol (used to treat gout);

  • antihistamines used to treat allergic reactions such as hay fever (e.g. mizolastine, terfenadine or astemizole);

  • corticosteroids (used to treat various conditions, including asthma and rheumatoid arthritis);

  • immunosuppressive medicines used to treat autoimmune disorders or to prevent organ rejection after transplantation (e.g. cyclosporine);

  • ritonavir, indinavir, nelfinavir (so-called protease inhibitors used to treat HIV infection);

  • medicines used to treat cancer;

  • ketoconazole, itraconazole (antifungal medicines);

  • halofantrine (used to treat certain forms of malaria);

  • pentamidine (used to treat pneumonia);

  • gold in injectable medicines (used to treat rheumatoid arthritis);

  • vinpocetine (used to treat symptomatic cognitive disorders in the elderly, including memory impairment);

  • bepridil, verapamil, diltiazem (heart medicines);

  • medicines used to treat heart rhythm disorders (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, ibutilide, dofetilide, digitalis, bretylium);

  • cisapride, difenoxin (used to treat gastrointestinal disorders);

  • digoxin or other cardiac glycosides (used to treat heart diseases);

  • baclofen (used to treat muscle stiffness, e.g. in multiple sclerosis);

  • medicines used to treat diabetes, e.g. insulin, metformin or gliptins;

  • calcium, including calcium supplements;

  • stimulant laxatives (e.g. senna);

  • non-steroidal anti-inflammatory drugs (e.g. ibuprofen) or high doses of salicylates (e.g. acetylsalicylic acid);

  • amphotericin B in injectable medicines (used to treat severe fungal infections);

  • medicines used to treat psychiatric disorders, e.g. depression, anxiety, schizophrenia (e.g. tricyclic antidepressants, neuroleptics such as amisulpride, sulpiride, sultopride, tiapride, haloperidol, droperidol);

  • tetracosactide (used to treat Crohn's disease);

  • trimethoprim (used to treat infections);

  • vasodilating medicines, including nitrates;

  • medicines used to treat low blood pressure, shock or asthma (e.g. ephedrine, noradrenaline or adrenaline);

  • Hypericum perforatum (St. John's wort);

  • dantrolene (used intravenously for serious temperature regulation disorders);

  • tacrolimus (used to modify the patient's immune system);

  • simvastatin (a medicine that lowers cholesterol levels);

  • cyclosporine (an immunosuppressive medicine);

  • medicines most commonly used to treat diarrhoea (racecadotril) or to prevent organ transplant rejection (sirolimus, everolimus, temsirolimus or other mTOR inhibitors). See section "Warnings and precautions".

Your doctor may need to adjust the dose and/or take additional precautions:

  • if you are taking an angiotensin II receptor antagonist (ARB) or aliskiren (see also information under "When not to use Co-Amlessa" and "Warnings and precautions").

Taking Co-Amlessa with food and drink
Co-Amlessa should be taken before meals.
Patients taking Co-Amlessa should not consume grapefruit juice or grapefruits, as they may increase blood levels of the active substance amlodipine, which could lead to an unexpected intensification of Co-Amlessa's blood pressure-lowering effect.
Pregnancy and breastfeeding
If the patient is pregnant or breastfeeding, suspects she may be pregnant, or is planning to have a child, she should consult her doctor or pharmacist before using this medicine.
Pregnancy
Inform your doctor if you are pregnant, suspect you may be pregnant, or are planning pregnancy. Your doctor will usually advise discontinuing Co-Amlessa before a planned pregnancy or immediately after pregnancy is confirmed, and will recommend an alternative medicine. Co-Amlessa is not recommended during the first trimester of pregnancy and must not be used after the 3rd month of pregnancy, as it may seriously harm the unborn child if used during this period.
Breastfeeding
It has been shown that small amounts of amlodipine pass into human milk.
Inform your doctor if you are breastfeeding or intend to breastfeed. Co-Amlessa is not recommended for use in breastfeeding women. Your doctor may recommend an alternative medicine if you wish to continue breastfeeding, especially if the infant is a newborn or premature. Seek immediate medical advice.
Driving and operating machinery
Co-Amlessa does not affect concentration, but dizziness or weakness due to low blood pressure may occur, which could impair the ability to drive or operate machinery. Do not drive or operate machinery until you know how you individually react to Co-Amlessa.
Co-Amlessa contains sodium
This medicine contains less than 1 mmol (23 mg) of sodium per tablet, meaning the medicine is considered "sodium-free".

3. How to take Co-Amlessa

This medicine should always be taken as directed by a physician or pharmacist. If in doubt,
consult a doctor or pharmacist.
The recommended dose is one tablet daily. It is recommended to take the tablet in the morning before a meal.
The tablet should be swallowed with a glass of water.
The appropriate dose for the patient will be determined by the physician. Co-Amlessa is intended for patients
already being treated with perindopril/indapamide and amlodipine as separate tablets.
Taking more Co-Amlessa than recommended
If more medicine has been taken than recommended, contact a doctor immediately or go to the nearest hospital emergency department.
The most likely adverse effect following overdose is hypotension. If a significant drop in arterial pressure occurs (symptoms such as dizziness or fainting), lie down with legs elevated.
Breathlessness due to fluid accumulation in the lungs (pulmonary oedema) may occur up to 24–48 hours after taking the medicine.
If you miss a dose of Co-Amlessa
It is important to take the medicine every day, as this ensures effective therapy. If a dose of Co-Amlessa is missed, take the next dose at the usual time.
Do not take a double dose to make up for a missed tablet.
Stopping Co-Amlessa
Since antihypertensive therapy is usually long-term, consult your doctor before stopping the medicine.
If you have any further doubts about using this medicine, consult your doctor or pharmacist.

4. Possible adverse reactions

Like any medicine, this medicine can cause adverse reactions, although not everyone will experience them.
If the patient experiences any of the following serious adverse reactions, the use of this medicine must be discontinued and immediate contact with a doctor is required:

  • Severe dizziness or fainting due to low blood pressure (common – may occur in up to 1 in 10 patients),
  • Bronchospasm (feeling of tightness in the chest, wheezing and shortness of breath) (uncommon – may occur in up to 1 in 100 patients),
  • Swelling of the face, lips, mouth, tongue or throat, breathing difficulties (angioedema, see section 2 “Warnings and precautions”) (uncommon – may occur in up to 1 in 100 patients),
  • Severe skin reactions, including erythema multiforme (skin rash often starting with red, itchy spots on the face, arms or legs) or severe skin rash, urticaria, redness of the entire skin surface, intense itching, blistering, peeling and swelling of the skin, mucosal inflammation (Stevens-Johnson syndrome), or other allergic reactions (very rare – may occur in up to 1 in 10,000 patients),
  • Cardiovascular disorders (heart rhythm disturbances, angina pectoris (chest pain radiating to the jaw and back, caused by physical exertion), myocardial infarction) (very rare – may occur in up to 1 in 10,000 patients),
  • Weakness of arms or legs, or speech disturbances, which may be signs of stroke (very rare – may occur in up to 1 in 10,000 patients),
  • Pancreatitis, which may cause severe upper abdominal pain radiating to the back, accompanied by very poor general condition (very rare – may occur in up to 1 in 10,000 patients),
  • Yellowing of the skin or eyes (jaundice), which may be a sign of hepatitis (very rare – may occur in up to 1 in 10,000 patients),
  • Life-threatening heart rhythm disturbances (frequency unknown),
  • Liver disease-induced brain disorder (hepatic encephalopathy) (frequency unknown),
  • Muscle weakness, cramps, tenderness or pain, particularly if the patient simultaneously feels unwell or has a high temperature, which may be due to abnormal muscle breakdown (frequency unknown).

Adverse reactions listed by decreasing frequency of occurrence may include:

  • Very common (may occur in more than 1 in 10 patients): oedema (fluid retention).
  • Common (may occur in up to 1 in 10 patients): skin reactions in patients with a tendency to allergic and asthmatic reactions, low blood potassium levels, headache, dizziness, balance disturbances, tingling and numbness, drowsiness, visual disturbances, feeling of emptiness in the head due to low blood pressure, tinnitus (sensation of noise in the ears), low blood pressure, palpitations (very rapid heartbeat), sudden reddening of the skin, especially the face (feeling of warmth or flushing), shortness of breath, cough, gastrointestinal disturbances (nausea, vomiting, abdominal pain, taste disturbances, changes in bowel rhythm, indigestion or digestive disturbances, diarrhoea, constipation), dryness of the oral mucosa, allergic reactions (such as skin rashes, itching), muscle cramps, ankle swelling, fatigue, feeling of tiredness.
  • Uncommon (may occur in up to 1 in 100 patients): inflammation of the nasal mucosa (nasal congestion or rhinitis), increased number of eosinophils (a type of white blood cells), hypoglycaemia (very low blood sugar levels), changes in laboratory test results: high blood potassium levels, transient after discontinuation of treatment, low blood sodium levels, which may lead to dehydration and low blood pressure,

mood changes, sleep disturbances, insomnia, depression, tremor, loss of pain sensation, tachycardia (rapid heartbeat), heart rhythm disturbances, vasculitis (inflammation of blood vessels), bronchospasm (chest tightness, wheezing and shortness of breath), angioedema (symptoms such as wheezing, swelling of the face or tongue), urticaria, formation of blister clusters on the skin, purpura (red spots on the skin), skin discoloration, sweating, alopecia, red or discoloured skin patches, photosensitivity reactions (increased skin sensitivity to sunlight), back, muscle or joint pain, kidney-related disorders, increased frequency of urination (especially at night), impotence (inability to achieve or maintain erection), breast enlargement in men, chest pain, pain, general malaise, fever, increased blood urea levels, increased blood creatinine levels, increased or decreased body weight, falls, fainting.
In patients with systemic lupus erythematosus (a type of collagenosis), symptoms may worsen.

  • Rare (may occur in up to 1 in 1,000 patients): disorientation, exacerbation of psoriasis, acute kidney failure, reduced or absent urine output, changes in laboratory test results: increased calcium levels, increased liver enzyme activity, high serum bilirubin levels, dark urine, nausea or vomiting, muscle cramps, disorientation and seizures. These may be symptoms of a condition called SIADH (syndrome of inappropriate antidiuretic hormone secretion), low blood chloride levels, low blood magnesium levels.
  • Very rare (may occur in up to 1 in 10,000 patients): changes in blood parameters, such as reduced number of white and red blood cells, reduced haemoglobin and haematocrit values, reduced platelet count, high blood glucose levels (hyperglycaemia), cardiovascular disorders (e.g. dyspnoea, myocardial infarction, stroke), eosinophilic pneumonia (a rare type of lung inflammation), gum oedema, pancreatitis, abdominal distension (gastritis), peripheral neuropathy (a condition causing loss of sensation, pain, inability to control muscles), severe skin symptoms (e.g. erythema multiforme). Abnormal liver function, hepatitis, yellowing of the skin (jaundice), increased liver enzyme activity, detected in blood tests.
  • Unknown (frequency cannot be estimated from available data): Abnormal heart function detected in ECG examination, changes in laboratory test results: high blood uric acid levels, myopia, blurred vision, visual impairment or eye pain due to increased pressure (possible symptoms of fluid accumulation in the vascular layer surrounding the eye – excessive fluid accumulation between the choroid and sclera – or acute angle-closure glaucoma), life-threatening heart rhythm disturbances (torsade de pointes tachycardia). In patients with liver impairment (liver disorders), there is a risk of developing hepatic encephalopathy (a condition causing brain damage). Tremor, postural rigidity, facial masking, slowed movements and shuffling gait, unsteady gait. Bluish discoloration, numbness and pain in fingers or toes (Raynaud's phenomenon).

Reporting of adverse reactions
If any adverse reactions occur, including any adverse reactions not listed in this leaflet, inform your doctor or pharmacist. Adverse reactions can be reported directly to the Department of Monitoring of Adverse Drug Reactions of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Al. Jerozolimskie 181C, 02-222 Warsaw
Tel.: + 48 22 49 21 301
Fax: + 48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the marketing authorisation holder.
Reporting of adverse reactions helps to provide more information on the safety of the medicine.

5. How to store Co-Amlessa

Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging following the abbreviation
"EXP". The expiry date refers to the last day of the stated month.
The batch number is indicated on the packaging after the abbreviation "Lot".
Do not store above 30°C.
Store in the original packaging to protect from light and moisture.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and other information

What Co-Amlessa contains

  • The active substances are perindopril with tert-butylamine, amlodipine (as besylate) and indapamide.
    Co-Amlessa 2 mg + 5 mg + 0.625 mg tablets: Each tablet contains 2 mg of perindopril with tert-butylamine, 5 mg of amlodipine (as besylate) and 0.625 mg of indapamide.
    Co-Amlessa 4 mg + 5 mg + 1.25 mg tablets: Each tablet contains 4 mg of perindopril with tert-butylamine, 5 mg of amlodipine (as besylate) and 1.25 mg of indapamide.
    Co-Amlessa 4 mg + 10 mg + 1.25 mg tablets: Each tablet contains 4 mg of perindopril with tert-butylamine, 10 mg of amlodipine (as besylate) and 1.25 mg of indapamide.
    Co-Amlessa 8 mg + 5 mg + 2.5 mg tablets: Each tablet contains 8 mg of perindopril with tert-butylamine, 5 mg of amlodipine (as besylate) and 2.5 mg of indapamide.
    Co-Amlessa 8 mg + 10 mg + 2.5 mg tablets: Each tablet contains 8 mg of perindopril with tert-butylamine, 10 mg of amlodipine (as besylate) and 2.5 mg of indapamide.
  • Other ingredients are: microcrystalline cellulose type 200, microcrystalline cellulose type 112, pregelatinized maize starch (type 1500), sodium carboxymethylstarch (type A), calcium chloride dihydrate, sodium hydrogen carbonate, colloidal anhydrous silica, magnesium stearate (E 470b). See section 2 "Co-Amlessa contains sodium".

What Co-Amlessa looks like and contents of the pack
Co-Amlessa 2 mg + 5 mg + 0.625 mg tablets: white to almost white, oval, biconvex tablets with a breakline on one side, 9 mm in length. The breakline on the tablet is intended only to facilitate breaking for easier swallowing and does not ensure equal dose division.
Co-Amlessa 4 mg + 5 mg + 1.25 mg tablets: white to almost white, round, slightly biconvex tablets with bevelled edges, 7 mm in diameter.
Co-Amlessa 4 mg + 10 mg + 1.25 mg tablets: white to almost white, oval, biconvex tablets with a breakline on one side, 12 mm in length. The breakline on the tablet is intended only to facilitate breaking for easier swallowing and does not ensure equal dose division.
Co-Amlessa 8 mg + 5 mg + 2.5 mg tablets: white to almost white, round, biconvex tablets with bevelled edges, 9 mm in diameter.
Co-Amlessa 8 mg + 10 mg + 2.5 mg tablets: white to almost white, round, biconvex tablets with a breakline on one side and bevelled edges, 9 mm in diameter. The breakline on the tablet is intended only to facilitate breaking for easier swallowing and does not ensure equal dose division.
Pack sizes: Blister packs containing 10, 14, 20, 28, 30, 56, 60, 84 and 90 tablets in a cardboard carton. Not all pack sizes may be marketed.
Marketing Authorisation Holder
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Manufacturer
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany
KRKA-POLSKA Sp. z o.o., ul. Równoległa 5, 02-235 Warszawa, Poland
For more detailed information on product names in other European Economic Area countries, please contact the local representative of the Marketing Authorisation Holder:
KRKA-POLSKA Sp. z o.o.
ul. Równoległa 5
02-235 Warszawa
Tel. 22 57 37 500